Authors' objectives: This health technology assessment evaluates the diagnostic test accuracy, clinical utility, and cost-effectiveness of noninvasive fetal RhD blood group genotyping. It also evaluates the budget impact of publicly funding noninvasive fetal RhD blood group genotyping, and the experiences, preferences, and values of people and health care providers related to care for RhD-incompatible pregnancies.
Fetal RhD Blood Group Genotyping; fetal rhD incompatibility; patient preferences; systematic review; clinical utility; cost-effectiveness; alloimmunized pregnancy; nonalloimmunized pregnancy
10.5
